Compare StocksMRNA vs NVDA

Moderna, Inc. (MRNA) vs NVIDIA Corporation (NVDA): Which Is the Better Buy in 2026?

As of 2026-06-19, MRNA is overvalued at $64, with a DCF intrinsic value of $6 and a margin of safety of -963%. NVDA is overvalued at $211, with an intrinsic value of $163 and a margin of safety of -29%. Of the two, NVDA has the wider margin of safety.

MRNA
Moderna, Inc.
$63.96
VS
NVDA
NVIDIA Corporation
$210.69

Rewards

MRNA
    NVDA
    • NVIDIA Corporation has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
    • Gross margin of 74.1% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
    • Free cash flow has grown at a 193.9% CAGR over the past 4 years, demonstrating strong earnings power growth.

    Risks

    MRNA
    • ROIC has declined by 67.4 percentage points over the past 4 years, which may signal competitive erosion.
    • Gross margin of -69.9% is low, suggesting a competitive or commodity-like market with limited pricing power.
    • Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.
    NVDA
    • FCF yield of 1.9% is below 3%, meaning the market is pricing in substantial future growth to justify the current price.
    • Beneish M-Score of -1.06 flags financial patterns consistent with potential earnings manipulation — warrants further investigation.
    • 39 insider sales with no purchases over the past 12 months — a persistent pattern of insider selling.

    Key Valuation Metrics

    Learn more →
    MRNA
    NVDA
    Valuation
    $-20.00M
    Free Cash Flow
    $96.68B
    -0.08%
    FCF Yield
    1.89%
    N/A
    Trailing P/E
    32.26
    -15.21
    Forward P/E
    16.55
    Quality & Moat
    -26.47%
    ROIC
    63.06%
    -36.56%
    ROE
    114.29%
    -69.89%
    Gross Margin
    74.14%
    N/A
    PEG Ratio
    0.64
    Balance Sheet Safety
    Net cash
    Net Debt / Equity
    Net cash
    N/A
    Interest Coverage
    N/A
    N/A
    Net Debt / EBITDA
    -0.24
    0.00%
    Dividend Yield
    0.02%
    MRNA: 2Ties: 1NVDA: 6
    MRNANVDA

    Historical Fundamentals

    Learn more →
    MRNA

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    NVDA

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    MRNA
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-11.10B
    Δ Market Cap
    $-57.53B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    NVDA
    $17.68
    created per $1 retained over 3 years
    Exceptional Value Creator
    Σ Retained
    $220.50B
    Δ Market Cap
    +$3.90T
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    MRNA
    962.8% Overvalued
    Price is 962.8% above estimated fair value
    Current Price: $63.96
    Fair Value: $6.02
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    NVDA
    44.3% Margin of Safety
    Price is 44.3% below estimated fair value
    Current Price: $210.69
    Fair Value: $378.18
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    MRNA

    Requires positive FCF to compute implied growth rate.

    NVDA

    What growth rate is the market pricing in at $211?

    +17.9%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +20.8%

    The market implies +17.9% Owner Earnings growth, below historical trends — potential opportunity.

    Standard FCF implies a more demanding +20.8%, reflecting heavy growth investment expected to generate future returns.

    Economic Moat Score

    Learn more →
    MRNA
    17/100
    No Moat
    70+ Wide · 40-69 Narrow · <40 None

    No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.
    NVDA
    69/100
    Narrow Moat
    70+ Wide · 40-69 Narrow · <40 None

    Narrow moat with roic consistency as the key competitive advantage. Improving revenue predictability would strengthen the moat.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

    Forensic Accounting

    Learn more →
    MRNA

    Insufficient data for Beneish M-Score calculation (requires 2+ years).

    NVDA
    -1.06
    Likely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    MRNA
    Insiders 7.3%Institutions 78.9%Retail & Other 13.7%
    No. of Institutional Holders1,044
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    NVDA
    Insiders 4.0%Institutions 70.9%Retail & Other 25.1%
    No. of Institutional Holders7,556
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    MRNA
    0
    Buys (3M)
    0
    Buys (12M)
    SAGAN PAUL L
    Director
    $1.00M
    @ $31.76 · 2025-03-03
    BANCEL STEPHANE J
    Chief Executive Officer
    $5.00M
    @ $31.22 · 2025-03-03
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    NVDA
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    MRNA
    3
    Sells (3M)
    6
    Sells (12M)
    Total value (12M): $11.57M
    KLINGER SHANNON THYME
    Officer
    $173,550
    @ $50.00 · 2026-06-04
    HOGE STEPHEN
    President
    $2.58M
    @ $48.40 · 2026-05-15
    HUSSAIN SHAH ABBAS
    Director
    $264,952
    @ $46.63 · 2026-05-01
    KLINGER SHANNON THYME
    Officer
    $726,047
    @ $52.29 · 2026-03-02
    HOGE STEPHEN
    President
    $7.81M
    @ $48.84 · 2026-02-23
    HUSSAIN SHAH ABBAS
    Director
    $13,910
    @ $27.60 · 2025-12-09
    HUSSAIN SHAH ABBAS
    Director
    $8,736
    @ $28.00 · 2025-06-11
    KLINGER SHANNON THYME
    Officer
    $23,637
    @ $44.68 · 2024-12-09
    KLINGER SHANNON THYME
    Officer
    $4,849
    @ $43.29 · 2024-12-03
    HOGE STEPHEN
    President
    $13,595
    @ $43.30 · 2024-12-03
    KLINGER SHANNON THYME
    Officer
    $60,675
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,452
    @ $42.79 · 2024-11-29
    MOCK JAMES M
    Chief Financial Officer
    $60,761
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,771
    @ $46.10 · 2024-11-11
    MOCK JAMES M
    Chief Financial Officer
    $42,986
    @ $60.12 · 2024-10-07
    KLINGER SHANNON THYME
    Officer
    $40,539
    @ $73.57 · 2024-09-09
    KLINGER SHANNON THYME
    Officer
    $8,777
    @ $76.99 · 2024-09-03
    HOGE STEPHEN
    President
    $24,483
    @ $76.99 · 2024-09-03
    KLINGER SHANNON THYME
    Officer
    $12,640
    @ $78.02 · 2024-08-29
    HOGE STEPHEN
    President
    $23,408
    @ $78.03 · 2024-08-29
    MOCK JAMES M
    Chief Financial Officer
    $12,640
    @ $78.02 · 2024-08-29
    KLINGER SHANNON THYME
    Officer
    $104,722
    @ $79.39 · 2024-08-28
    MOCK JAMES M
    Chief Financial Officer
    $104,881
    @ $79.40 · 2024-08-28
    HOGE STEPHEN
    President
    $21,363
    @ $84.11 · 2024-08-12
    AFEYAN NOUBAR BOGHOS
    Director
    $1.80M
    @ $119.96 · 2024-07-31
    AFEYAN NOUBAR BOGHOS
    Director
    $1.77M
    @ $117.80 · 2024-07-24
    AFEYAN NOUBAR BOGHOS
    Director
    $1.84M
    @ $122.84 · 2024-07-17
    HOGE STEPHEN
    President
    $1.82M
    @ $121.12 · 2024-07-15
    AFEYAN NOUBAR BOGHOS
    Director
    $1.76M
    @ $117.08 · 2024-07-10
    MOCK JAMES M
    Chief Financial Officer
    $81,465
    @ $118.24 · 2024-07-08
    AFEYAN NOUBAR BOGHOS
    Director
    $1.91M
    @ $127.22 · 2024-06-26
    AFEYAN NOUBAR BOGHOS
    Director
    $2.00M
    @ $133.57 · 2024-06-18
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    NVDA
    1
    Sells (3M)
    39
    Sells (12M)
    Total value (12M): $1.09B
    DABIRI JOHN O
    Director
    $133,750
    @ $214.00 · 2026-05-27
    ROBERTSON DONALD F JR
    Officer
    $942,944
    @ $174.75 · 2026-03-20
    SHAH AARTI S
    Director
    $3.36M
    @ $176.71 · 2026-03-19
    DABIRI JOHN O
    Director
    $555,440
    @ $184.90 · 2026-03-13
    ROBERTSON DONALD F JR
    Officer
    $15.19M
    @ $189.85 · 2026-01-02
    ROBERTSON DONALD F JR
    Officer
    $4.43M
    @ $179.98 · 2025-12-19
    DABIRI JOHN O
    Director
    $112,317
    @ $179.42 · 2025-11-24
    HUANG JEN-HSUN
    Chief Executive Officer
    $5.20M
    @ $207.91 · 2025-10-29
    HUANG JEN-HSUN
    Chief Executive Officer
    $23.56M
    @ $188.47 · 2025-10-28
    HUANG JEN-HSUN
    Chief Executive Officer
    $40.73M
    @ $181.04 · 2025-10-23
    HUANG JEN-HSUN
    Chief Executive Officer
    $41.06M
    @ $182.48 · 2025-10-20
    HUANG JEN-HSUN
    Chief Executive Officer
    $41.34M
    @ $183.73 · 2025-10-15
    HUANG JEN-HSUN
    Chief Executive Officer
    $42.89M
    @ $190.60 · 2025-10-10
    HUANG JEN-HSUN
    Chief Executive Officer
    $42.05M
    @ $186.89 · 2025-10-07
    HUANG JEN-HSUN
    Chief Executive Officer
    $42.09M
    @ $187.08 · 2025-10-02
    HUANG JEN-HSUN
    Chief Executive Officer
    $40.23M
    @ $178.82 · 2025-09-29
    HUANG JEN-HSUN
    Chief Executive Officer
    $40.21M
    @ $178.69 · 2025-09-24
    HUANG JEN-HSUN
    Chief Executive Officer
    $39.18M
    @ $174.14 · 2025-09-19
    ROBERTSON DONALD F JR
    Officer
    $617,298
    @ $176.37 · 2025-09-19
    HUANG JEN-HSUN
    Chief Executive Officer
    $39.75M
    @ $176.66 · 2025-09-16
    HUANG JEN-HSUN
    Chief Executive Officer
    $39.28M
    @ $174.59 · 2025-09-11
    HUANG JEN-HSUN
    Chief Executive Officer
    $38.01M
    @ $168.95 · 2025-09-08
    HUANG JEN-HSUN
    Chief Executive Officer
    $38.61M
    @ $171.60 · 2025-09-03
    HUDSON BEACH DAWN E
    Director
    $15.38M
    @ $170.90 · 2025-09-03
    HUANG JEN-HSUN
    Chief Executive Officer
    $27.12M
    @ $180.79 · 2025-08-15
    HUANG JEN-HSUN
    Chief Executive Officer
    $40.96M
    @ $182.04 · 2025-08-13
    HUANG JEN-HSUN
    Chief Executive Officer
    $40.66M
    @ $180.70 · 2025-08-08
    HUANG JEN-HSUN
    Chief Executive Officer
    $39.78M
    @ $176.80 · 2025-08-05
    HUANG JEN-HSUN
    Chief Executive Officer
    $40.18M
    @ $178.58 · 2025-07-31
    HUANG JEN-HSUN
    Chief Executive Officer
    $39.16M
    @ $174.02 · 2025-07-28
    HUANG JEN-HSUN
    Chief Executive Officer
    $38.22M
    @ $169.87 · 2025-07-23
    HUANG JEN-HSUN
    Chief Executive Officer
    $38.71M
    @ $172.05 · 2025-07-18
    HUANG JEN-HSUN
    Chief Executive Officer
    $37.59M
    @ $167.08 · 2025-07-15
    HUANG JEN-HSUN
    Chief Executive Officer
    $36.43M
    @ $161.91 · 2025-07-10
    HUANG JEN-HSUN
    Chief Executive Officer
    $35.55M
    @ $158.02 · 2025-07-07
    HUANG JEN-HSUN
    Chief Executive Officer
    $35.16M
    @ $156.27 · 2025-07-01
    HUANG JEN-HSUN
    Chief Executive Officer
    $30.47M
    @ $152.33 · 2025-06-26
    HUANG JEN-HSUN
    Chief Executive Officer
    $14.40M
    @ $144.04 · 2025-06-23
    ROBERTSON DONALD F JR
    Officer
    $646,469
    @ $143.66 · 2025-06-20
    BURGESS ROBERT KENNETH
    Director
    $6.74M
    @ $134.82 · 2025-05-30
    DABIRI JOHN O
    Director
    $91,608
    @ $138.80 · 2025-05-30
    KRESS COLETTE M.
    Chief Financial Officer
    $7.79M
    @ $116.83 · 2025-03-21
    ROBERTSON DONALD F JR
    Officer
    $525,585
    @ $116.80 · 2025-03-21
    SHAH AARTI S
    Director
    $2.37M
    @ $118.42 · 2025-03-20
    BURGESS ROBERT KENNETH
    Director
    $6.16M
    @ $115.49 · 2025-03-13
    DABIRI JOHN O
    Director
    $292,930
    @ $110.00 · 2025-03-10
    KRESS COLETTE M.
    Chief Financial Officer
    $9.03M
    @ $135.40 · 2024-12-13
    ROBERTSON DONALD F JR
    Officer
    $608,775
    @ $135.28 · 2024-12-13
    DABIRI JOHN O
    Director
    $101,672
    @ $142.00 · 2024-11-25
    KRESS COLETTE M.
    Chief Financial Officer
    $7.77M
    @ $116.59 · 2024-09-20
    ROBERTSON DONALD F JR
    Officer
    $524,293
    @ $116.51 · 2024-09-20
    HUANG JEN-HSUN
    Chief Executive Officer
    $28.55M
    @ $118.97 · 2024-09-13
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    MRNA
    FearGreed
    😏Greed(61/100)

    "Market is optimistic — be cautious and ensure you have a margin of safety"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    NVDA
    FearGreed
    😐Neutral(56/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    MRNA
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Greed (61)
    NVDA
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (56)
    View MRNA Full AnalysisView NVDA Full Analysis

    Frequently Asked Questions: MRNA vs NVDA

    Is Moderna, Inc. or NVIDIA Corporation more undervalued in 2026?

    Based on our discounted cash flow model, NVDA trades at a -29.0% margin of safety (intrinsic value $163 vs. price $211), compared to MRNA's -962.8% margin of safety (intrinsic $6 vs. $64).

    Which stock has a wider economic moat, Moderna, Inc. or NVIDIA Corporation?

    NVDA scores 69/100 (Narrow moat), while MRNA scores 17/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is Moderna, Inc. in financial distress?

    MRNA's Altman Z-Score of 2.5 places it in the Grey zone, signaling elevated bankruptcy risk. NVDA scores 66.7 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which company has better free cash flow, Moderna, Inc. or NVIDIA Corporation?

    NVIDIA Corporation (NVDA) generates a 1.9% free cash flow yield, compared to Moderna, Inc.'s -0.1%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

    Which stock has higher return on invested capital, Moderna, Inc. or NVIDIA Corporation?

    NVDA earns 63.1% ROIC versus MRNA's -26.5%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

    Does NVIDIA Corporation have accounting red flags?

    NVDA's Beneish M-Score of -1.1 flags it as a likely earnings manipulator (above the -1.78 threshold). By contrast, MRNA scores N/A, within the normal range. The Beneish model detects aggressive accounting through eight financial ratios.